Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Alltest Biotech CoSHSE:688606 +1.04%53 Return-on-Tangible-Equity is 2.05% as of Mar. 2026, which is 94% below its 10-year median of 34.09. GuruFocus rates SHSE:688606 with a GF Score™ of 53/100 and a GF Value™ of ¥85.89 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Hangzhou Alltest Biotech Co ranks better than 51.32% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hangzhou Alltest Biotech Co's annualized net income for the quarter that ended in Mar. 2026 was ¥77.6 Mil. Hangzhou Alltest Biotech Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥3,778.7 Mil. Therefore, Hangzhou Alltest Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 2.05%.
The historical rank and industry rank for Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688606'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.64 Med: 34.09 Max: 111.27
Current: 4.71
During the past 10 years, Hangzhou Alltest Biotech Co's highest Return-on-Tangible-Equity was 111.27%. The lowest was 4.64%. And the median was 34.09%.
SHSE:688606's Return-on-Tangible-Equity is ranked better than 51.32% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs SHSE:688606: 4.71
Hangzhou Alltest Biotech Co (SHSE:688606) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hangzhou Alltest Biotech Co Return-on-Tangible-Equity Related Terms
Hangzhou Alltest Biotech Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Alltest Biotech Co Return-on-Tangible-Equity Chart
SHSE:688606 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.05% mean?
Hangzhou Alltest Biotech Co (SHSE:688606) has a Return-on-Tangible-Equity of 2.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hangzhou Alltest Biotech Co and its competitors. This is 94% below median its historical median of 34.09. Over the past decade, Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity has ranged from 4.64 to 111.27. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #369 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 48.7%.
Is Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity too high?
Hangzhou Alltest Biotech Co's current Return-on-Tangible-Equity of 2.05% is 94% below median its 10-year median of 34.09. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 111.27. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Hangzhou Alltest Biotech Co's value of 2.05% is 49.8% below this industry median. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #369 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #369 out of 758 companies for Return-on-Tangible-Equity. This puts Hangzhou Alltest Biotech Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Hangzhou Alltest Biotech Co's value of 2.05% is 49.8% below this benchmark. Historically, Hangzhou Alltest Biotech Co's own Return-on-Tangible-Equity has ranged from 4.64 to 111.27 over the past decade. While the company's 10-year median is 34.09 vs. the industry median of 4.08, Hangzhou Alltest Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Alltest Biotech Co's current Return-on-Tangible-Equity of 2.05% is 49.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hangzhou Alltest Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Alltest Biotech Co's current Return-on-Tangible-Equity is 2.05%, which is 94% below median its own 10-year median of 34.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥85.89, compared to a current price of ¥43.92 — trading 48.9% below its estimated fair value. The current Return-on-Tangible-Equity is 2.05%, which is 94% below median its 10-year median of 34.09 and 49.8% below the Medical Devices & Instruments industry median of 4.08. Hangzhou Alltest Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current Return-on-Tangible-Equity is 2.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥43.92 is trading 48.9% below its estimated GF Value™ of ¥85.89.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
Return-on-Tangible-Equity: 2.05% (94% below median its 10-year median of 34.09)
GF Value™: ¥85.89 vs. price of ¥43.92 (48.9% below fair value)
Industry Position: 49.8% below the Medical Devices & Instruments median (#369 of 758)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
